Watson Reports Positive Phase III Data for Prostate and Bladder Drugs
redorbit.com     May 22, 2008            

Watson Pharmaceuticals has announced positive data from clinical studies on two Phase III products - silodosin, an investigational treatment for benign prostatic hyperplasia and oxybutynin chloride topical gel, an investigational product for overactive bladder. [read full story]                    


View all news articles about*:
Datamonitor Health Hyperplasia Male Pharmaceuticals Prostatic Watson
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

                   

Find The Best Over-The-Counter Drug For You

cbs4boston.com     18 hrs ago          

BOSTON (WBZ) ― We have all wandered the aisles of a drug store searching for the right over-the-counter medicine to relieve symptoms of everything from a cold to heartburn, but the choices can be overwhelming. The American...                    

comments

Tadalafil shows promise for relief of lower urinary tract symptoms associated with BPH

brightsurf.com     yesterday   4 related          

Men with signs of benign prostatic hyperplasia (BPH) can be helped with a daily dose of erectile dysfunction drug tadalafil (Cialis®) to relieve associated lower urinary tract symptoms (LUTS), according to a new study published...                    

comments

                   

Trimedyne Reports a Net Loss for the Quarter Ended June 30, 2008

redorbit.com     yesterday   1 related          

TRIMEDYNE, INC. (OTCBB: TMED) today announced its financial results for the quarter and nine months ended June 30, 2008. Revenues for the quarter were $1,385,000, an increase of 16% from revenues of $1,197,000 for the prior...                    

comments

                   

Trimedyne Reports a Net Loss for the Quarter Ended June 30, 2008

marketwire.com     yesterday   48 related          

LAKE FOREST, CA--(Marketwire - August 19, 2008) - TRIMEDYNE, INC. (OTCBB: TMED) today announced its financial results for the quarter and nine months ended June 30, 2008. Revenues for the quarter were $1,385,000, an increase of...                    

comments